{
    "clinical_study": {
        "@rank": "23353", 
        "arm_group": [
            {
                "arm_group_label": "low dose ASP7991", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "middle dose ASP7991", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "high dose ASP7991", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is to assess the safety, tolerability, plasma concentration and pharmacodynamics\n      of ASP7991 after multiple oral administrations to non-elderly subjects."
        }, 
        "brief_title": "Multiple Oral Administration of ASP7991 to Non-elderly Male Subjects", 
        "completion_date": {
            "#text": "February 2013", 
            "@type": "Actual"
        }, 
        "condition": [
            "Healthy", 
            "Pharmacokinetics of ASP7991"
        ], 
        "detailed_description": {
            "textblock": "In each step (lowest dose, middle dose, highest dose), subjects are randomly assigned in a\n      double blinded manner to receive either ASP7991 (n=9) or Placebo (n=3) and are administered\n      repeatedly. Once daily, the subjects are administered ASP7991 or placebo orally 30 minutes\n      after breakfast with 150 mL water for 7 days. After the each step the sponsor evaluates the\n      safety in the blinded manner for deciding an escalation to the step."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy, as judged by the investigator/sub investigator based on the results of\n             physical examination obtained before study drug administration\n\n          -  Body weight: \u226550.0 kg, <80.0 kg\n\n          -  BMI: \u226517.6, <26.4\n\n          -  Serum corrected calcium concentration: \u22659.0mg/dL, <10.4 mg/dL\n\n        Exclusion Criteria:\n\n          -  Received any investigational drugs in other clinical or post-marketing studies within\n             120 days before screening\n\n          -  Donated 400 mL of whole blood within 90 days, 200 mL of whole blood within 30 days,\n             or blood components within 14 days before screening\n\n          -  Received medication (including marketed drug) within 7 days before hospitalization,\n             vitamin preparation including vitamin D and supplement including calcium or is\n             scheduled to receive medication\n\n          -  A deviation from normal criteria range of 12-lead ECG (QT evaluation)\n\n          -  A deviation from the normal range in clinical laboratory tests\n\n          -  Highly sensitive cardiac troponin T (at screening): \u22650.014 ng/mL\n\n          -  History of drug allergies\n\n          -  Upper gastrointestinal disease (e.g. nausea, vomiting, stomachache) within 7 days\n             before admission\n\n          -  Concurrent or previous hepatic disease (e.g., viral hepatitis, drug-induced liver\n             injury)\n\n          -  Concurrent or previous endocrine disorders (e.g., hyperthyroidism, aberration in\n             growth hormone)"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "36", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "June 5, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01872013", 
            "org_study_id": "7991-CL-1002"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "low dose ASP7991", 
                    "middle dose ASP7991", 
                    "high dose ASP7991"
                ], 
                "description": "oral", 
                "intervention_name": "ASP7991", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "oral", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Plasma concentration", 
            "Urinary concentration", 
            "ASP7991"
        ], 
        "lastchanged_date": "June 5, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Tokyo", 
                    "country": "Japan"
                }
            }
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "4", 
        "official_title": "Randomized, Double-blinded, Placebo-controlled, Multiple Oral Administration of ASP7991 to Non-elderly Male Subjects", 
        "overall_official": {
            "affiliation": "Astellas Pharma Inc", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Japan: Pharmaceuticals and Medical Devices Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "February 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "The safety of ASP7991 assessed by the incidence of adverse events, vital signs, laboratory tests, 12-lead ECGs, ECGs for QT evaluation and slit lamp examination", 
            "safety_issue": "Yes", 
            "time_frame": "For 96 hours after dosing"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01872013"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Plasma concentrations unchanged drug; AUC24h, Cmax, Ctrough, tmax, t1/2, CL/F, Vz/F", 
                "safety_issue": "No", 
                "time_frame": "For 96 hours after dosing"
            }, 
            {
                "measure": "Urinary concentrations unchanged drug; Aelast, Aelast%, CLR", 
                "safety_issue": "No", 
                "time_frame": "For 96 hours after dosing"
            }
        ], 
        "source": "Astellas Pharma Inc", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Astellas Pharma Inc", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}